Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Patient Preference and Adherence
|
May 17, 2021
Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status
Efrat Neter, Lea Glass-Marmor, Loren Haiien, et al.
Multiple Sclerosis and Related Disorders
|
October 15, 2022
Medication habits among persons with multiple sclerosis
Efrat Neter, Lea Glass-Marmor, Anat Wolkowitz, et al.
Plos One
|
May 5, 2021
Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis
Daniel Golan, Smadar Sagiv, Lea Glass-Marmor, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
September 1, 2020
Mobile phone-based e-diary for assessment and enhancement of medications adherence among patients with multiple sclerosis
Daniel Golan, Smadar Sagiv, Lea Glass-Marmor, et al.
International Immunology
|
July 18, 2006
Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis
Doron Melamed, Orit Messika, Lea Glass-Marmor, et al.
Journal of Neuroimmunology
|
March 31, 2009
Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses
Lea Glass-Marmor, Tamar Paperna, Yanna Galboiz, et al.
European Neurology
|
June 9, 2005
Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's disease
Michael Inspector, Judith Aharon-Perez, Lea Glass-Marmor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 24, 2006
Chronotherapy using corticosteroids for multiple sclerosis relapses
Lea Glass-Marmor, Tamar Paperna, Yaara Ben-Yosef, et al.
International Journal of Molecular Sciences
|
May 4, 2026
Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) Treatments
Elsebeth Staun-Ram, Anat Volkowich, Lea Glass-Marmor, et al.
BMC Neurology
|
March 25, 2021
Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis
Efrat Neter, Lea Glass-Marmor, Anat Wolkowitz, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Patient Preference and Adherence
|
May 17, 2021
Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status
Efrat Neter, Lea Glass-Marmor, Loren Haiien, et al.
Multiple Sclerosis and Related Disorders
|
October 15, 2022
Medication habits among persons with multiple sclerosis
Efrat Neter, Lea Glass-Marmor, Anat Wolkowitz, et al.
Plos One
|
May 5, 2021
Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis
Daniel Golan, Smadar Sagiv, Lea Glass-Marmor, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
September 1, 2020
Mobile phone-based e-diary for assessment and enhancement of medications adherence among patients with multiple sclerosis
Daniel Golan, Smadar Sagiv, Lea Glass-Marmor, et al.
International Immunology
|
July 18, 2006
Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis
Doron Melamed, Orit Messika, Lea Glass-Marmor, et al.
Journal of Neuroimmunology
|
March 31, 2009
Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses
Lea Glass-Marmor, Tamar Paperna, Yanna Galboiz, et al.
European Neurology
|
June 9, 2005
Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's disease
Michael Inspector, Judith Aharon-Perez, Lea Glass-Marmor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 24, 2006
Chronotherapy using corticosteroids for multiple sclerosis relapses
Lea Glass-Marmor, Tamar Paperna, Yaara Ben-Yosef, et al.
International Journal of Molecular Sciences
|
May 4, 2026
Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) Treatments
Elsebeth Staun-Ram, Anat Volkowich, Lea Glass-Marmor, et al.
BMC Neurology
|
March 25, 2021
Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis
Efrat Neter, Lea Glass-Marmor, Anat Wolkowitz, et al.
Page
of 3